Lantus & You journal for Lantus SoloSTAR (insulin glargine [rDNA origin] injection pen). Manufactured by Sanofi (Bridgewater, NJ). Entry submitted by IDEO (Cambridge, MA). The Lantus & You journal ...
Hosted on MSN
Lantus in today’s diabetes treatment landscape
Lantus, a long-acting insulin glargine, offers stable 24-hour blood sugar control for people with type 1 and type 2 diabetes. It is often introduced when other treatments are insufficient, and can be ...
The US Court of Appeals for the First Circuit last week ruled that Sanofi improperly submitted a patent for its insulin device in the US Food and Drug Administration’s (FDA) Orange Book and could ...
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (NASDAQ: GDRX), a leading resource for healthcare savings and information, today announced it is working with Sanofi (NASDAQ: SNY), a global leader in ...
NEW YORK/WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Wednesday cast doubt on recent studies that suggested possible cancer risk with Sanofi-Aventis' widely used Lantus diabetes ...
(RTTNews) - Sandoz Group AG (SDZ.SW) announced that the European Commission has approved Ondibta (insulin glargine), a biosimilar to Sanofi's Lantus SoloStar, for the treatment of diabetes mellitus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results